Skip to content
Oncology Research Hub

Atlanta, Georgia

Cancer clinical trials in Atlanta, GA

243 cancer studies are recruiting participants at sites in Atlanta as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Atlanta at a glance

  • 243 studies are recruiting at a site in Atlanta.
  • By phase: Early Phase 1 (2), Phase 1 (41), Phase 1/2 (32), Phase 2 (54), Phase 2/3 (6), Phase 3 (70), Phase 4 (2), No phase (13), Observational (23). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (132), university, hospital or other (93), government (18).
  • By research area: Lung Cancer (65), Breast Cancer (61), Lymphoma (57), Prostate Cancer (30), Pancreatic Cancer (18), Melanoma (12).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Atlanta

Basic details from each study's public record (the 30 most recently updated of 243). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    Emory University School of Medicine
    Registry record
    NCT05696626 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Winship Cancer Institute at Emory University
    Registry record
    NCT07488676 · updated
  3. A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Emory University Hospital · Emory University Hospital Midtown · Grady Memorial Hospital
    Registry record
    NCT07748208 · updated
  4. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Emory University Hospital/Winship Cancer Institute · Northside Hospital
    Registry record
    NCT03418961 · updated
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06058377 · updated
  6. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Winship Cancer Institute of Emory University
    Registry record
    NCT06270706 · updated
  7. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Winship Cancer Institute, Emory University
    Registry record
    NCT06638307 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Lung cancer studies recruiting in Atlanta

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06287775 · updated
  2. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    Emory University
    Registry record
    NCT06983743 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Emory Winship Cancer Institute
    Registry record
    NCT07659782 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Northside Hospital
    Registry record
    NCT04267848 · updated
  5. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Winship Cancer Institute
    Registry record
    NCT04886804 · updated
  6. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06498635 · updated
  7. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Emory Winship
    Registry record
    NCT07080242 · updated
  8. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Piedmont Healthcare
    Registry record
    NCT07100080 · updated
  9. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Piedmont Atlanta Hospital ( Site 0121)
    Registry record
    NCT07554339 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Atlanta

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT03866382 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    Emory University
    Registry record
    NCT04221542 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Melanoma studies recruiting in Atlanta

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Atlanta, GA on ClinicalTrials.gov.

Lymphoma studies recruiting in Atlanta

  1. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

    • No phase
    • Ages 1 to 25
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Healthcare of Atlanta
    Registry record
    NCT05621291 · updated
  2. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06724237 · updated
  3. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Arthur M Blank Hospital
    Registry record
    NCT06173518 · updated
  4. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT03739814 · updated
  5. Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT04301076 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Healthcare of Atlanta - Arthur M Blank Hospital
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Healthcare of Atlanta - Arthur M Blank Hospital · Emory Proton Therapy Center · Emory Saint Joseph's Hospital
    Registry record
    NCT05675410 · updated
  8. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06337318 · updated
  9. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study sites
    Emory University Winship Cancer Institute · Northside Cancer Center
    Registry record
    NCT06846671 · updated
  10. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT07003295 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Atlanta, GA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Atlanta

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US023
    Registry record
    NCT07522073 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Ask about studies near Atlanta

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call